Dr. José Mangione Inaugurated as New SOLACI President

Dr. José Mangione, renowned Latin American interventional cardiologist of ample trajectory, is now in charge of the Latin American Interventional Cardiology’s destiny for the next two years, following Dr. José Luis Leiva Pons’ (Mexico) successful administration.

Dr. José Mangione will preside SOLACI during the term 2019-2021. PH: Antônio More / MorePress.

“I am honored and delighted to take this responsibility”, stated Dr. Mangione during the closing ceremony of SOLACI-SBHCI 2019. And added: “SOLACI has been conducted by many of the great names of Latin American Interventional Cardiology. SOLACI is a strong notable brand with a solid reputation around the world. My job will be to keep uniting cardiovascular intervention across the region.

Trained at Mogi das Cruzes University, Dr. Mangione is the former President of the Brazilian Society of Hemodynamics and Interventional Cardiology (SHBCI) in addition to having been the former Vice-President to Dr. Leiva Pons at SOLACI. Thus, he certainly knows the ropes of our society.

His first words as president emphasized the importance of hard work in the scientific area at SOLACI: “My concern, responsibility and determination is to further develop the scientific part of SOLACI, (…) we must continue working with our local societies in depth to show the world that Latin America is capable of world class interventionism”..

Dr. Leiva Pons bid farewell to SOLACI Presidency. PH: Antônio More / MorePress.

Dr. Mangione will be assisted as Vice President by Dr. Anibal Damonte, current President of the Argentinian School of Interventional Cardiologists (CACI) and founding member of SOLACI. Dr. Alfaro Marchena Noriega (Panama) will continue to be the Secretary and Dr. Omar Santaera (Argentina) will continue as our institution’s Treasurer.

On the other hand, during the closing ceremony Dr. José Luis Leiva Pons pointed out the success of SOLACI-SBHCI 2019 (“An event with excellent attendance and the presence of international professors of the highest category”), he thanked the authorities (Dra. Viviana Lemke, President of SBHCI, and Dr. Alexandre Schaan of Quadros, President of the event’s Scientific Commettee) and praised the work done throughout the year: “we have worked hard to get where we are and are extremely pleased with the result. We are grateful for the presence of you all”.

He finally said goodbye: “We leave SOLACI in great hands. See you at Buenos Aires 2020”..


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...